Monthly Archives: December 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baozun, Inc. – BZUN

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Baozun, Inc. ("Baozun" or the "Company") (NASDAQ: BZUN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Baozun and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On November 21, 2019, Baozun announced financial results for the third quarter of 2019 that were below market expectations and provided disappointing financial guidance for the fourth quarter of 2019, citing, in large part, the adverse "impact from terminating our service agreement with one electronics brand." Though Baozun did not disclose the identity of the "electronics brand" at issue, many members of the financial media have suggested that the disclosure referred to Huawei Technologies Co., Ltd.

On this news, Baozun's American Depository Receipt price fell $7.60 per share, or 17.47%, to close at $35.90 per share on November 21, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 570459

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

LONDON, UK / ACCESSWIRE / December 16, 2019 / Midatech (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 11 December 2019, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing 20 ordinary shares of the Company, for the 30 consecutive business days beginning 29 October 2019, the Company no longer meets the minimum bid price requirement.

The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP."

In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 8 June 2020 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the bid price of the Depositary Shares must meet or exceed $1.00 per share for at least ten consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel.

The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods.

The Company's business operations are not affected by the receipt of the Notification Letter.

The Company's ordinary shares are listed on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with such listing.

– Ends –

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Stephen Stamp, CFO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our plans, including those related to the Company's intentions in response to the Notification Letter, the Company's continued compliance with the NASDAQ Listing Rules, and the Company's intentions during the Compliance Period and after. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

ReleaseID: 570451

KESSLER TOPAZ MELTZER & CHECK, LLP: Reminds Investors of Final Deadline Approaching in Securities Fraud Class Action Lawsuit Filed Against iRobot Corporation

RADNOR, PA / ACCESSWIRE / December 16, 2019 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds iRobot Corporation (NASDAQ:IRBT) ("iRobot") investors that the firm has filed a securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired iRobot stock between November 21, 2016 and October 22, 2019, inclusive (the "Class Period").

REMINDER: Investors who purchased or otherwise acquired iRobot securities during the Class Period may, no later than December 23, 2019, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please visit: https://www.ktmc.com/irobot-securities-class-action?utm_source=PR&utm_medium=Link&utm_campaign=irobot.

iRobot is a global consumer robot company that designs and builds robots to assist with household tasks and has sold more than 25 million robots worldwide. iRobot's most popular product line is its autonomous robotic vacuum cleaners, which iRobot first introduced with the Roomba Vacuuming Robot in 2002. iRobot's products, including the Roomba line, purport to feature proprietary technologies and advanced concepts in cleaning, mapping, and navigation.

The Class Period commences on November 21, 2016, when iRobot announced it would acquire the iRobot-related distribution business of privately-held, Tokyo-based Sales on Demand Corporation. In a press release that day, iRobot said the acquisition would "better enable iRobot to maintain its leadership position and accelerate the growth of its business in Japan through direct control of pre- and post-sales market activities including sales, marketing, branding, channel relationships and customer service."

On April 23, 2019, after the close of trading, iRobot surprised the market when it announced that quarterly revenues were below analyst expectations and also revealed surging inventory levels. Specifically, iRobot reported days in inventory ("DII") of 140 for the three months ended March 30, 2019, compared to DII of 101 for the three months ended March 31, 2018. Inventory also rose to $181 million as of March 30, 2019, up from $112 million in April 2018. Following this news, iRobot's stock price fell from $130.57 per share on April 23, 2019, to $100.42 per share on April 24, 2019, a decline of over 23% in one trading day.

On July 23, 2019, after the close of trading, iRobot cut its full-year earnings forecast. Specifically, fiscal year 2019 revenue guidance was lowered from a range between $1.28 billion and $1.31 billion, to a range between $1.2 billion and $1.25 billion, and earnings per share guidance was lowered from a range between $3.15 and $3.40 to a range between $2.40 and $3.15. Following this news, iRobot's stock price fell from $89.63 per share on July 23, 2019, to $74.51 per share on July 24, 2019, a decline of nearly 17% in one trading day.

On October 22, 2019, after the close of trading, iRobot issued a press release reporting third quarter 2019 financial results. iRobot cut the high end of its revenue expectations for the year, from $1.25 billion to $1.21 billion, and said it rolled back price increases after a "suboptimal" customer response. iRobot reported increased inventory levels once again, with third quarter 2019 ending inventory of $248 million or 149 DII compared to the $161 million or 113 DII a year prior. Following this news, iRobot's stock price fell from $54.03 per share on October 22, 2019, to $49.06 per share on October 23, 2019, a decline of over 9% in one trading day.

The complaint alleges that, throughout the Class Period, iRobot reported explosive, double-digit revenue growth, which it attributed to increasing demand for its Roomba products, expanded gross margin due to distributor acquisitions, greater brand awareness and technological innovation. In reality, iRobot was engaging in channel-stuffing in order to inflate its sales and revenues figures, and had acquired two of its largest distributors in order to facilitate and conceal this deceptive practice. As a result of these misrepresentations, iRobot shares traded at artificially inflated prices throughout the Class Period.

Investors who wish to discuss this securities fraud class action lawsuit and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (844) 887-9500 (toll free) or at info@ktmc.com.

iRobot investors may, no later than December 23, 2019, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 570167

SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Plantronics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Plantronics, Inc. ("Plantronics" or "the Company") (NYSE:PLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 2, 2018 and November 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 13, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Plantronics engaged in channel stuffing to artificially increase its sales figures. The Company failed to maintain appropriate internal controls on inventory. Plantronics failed to monitor inventory levels before the introduction of new product models which would lower demand for older stock. Based on these facts, the Company's public statements throughout the class period were false and materially misleading. When the market learned the truth about Plantronics, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570441

SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against X Financial and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of X Financial ("X Financial" or "the Company") (NYSE:XYF) for violations of the securities laws. The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of X Financial ("X Financial" or "the Company") (NYSE:XYF) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. X Financial's third quarter of 2018 ended just 11 days after the Company's September 2018 IPO. The Company's results for the quartered showed it was suffering from an increase in delinquency rates, a reduction in loans, and a shrinking number of active lenders on its platform. The Company's CEO admitted on March 19, 2019, that its loan volume had been decreasing since the middle of 2018, before its IPO. The Company's Chairman and CEO disclosed on May 21, 2019, that it would be unlikely to achieve significant growth due to the failure of its preferred loan business. Since X Financial's IPO, it has traded as low as $1.65 per ADS compared to its $9.50 per ADS IPO.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570440

Progressive Planet Solutions Announces Approval of Consolidation

VANCOUVER, BC / ACCESSWIRE / December 16, 2019 / PROGRESSIVE PLANET SOLUTIONS INC. (PLAN-TSX:V) ("Progressive Planet", "PLAN" or the "Company") announces that, further to its news release dated December 4, 2019, effective Friday, December 20, 2019 at market open, the Company will consolidate its common shares on the basis of one (1) post-consolidation common share for every three (3) pre-consolidation common shares.

The Company will have a total of approximately 22,139,712 post-consolidation common shares issued and outstanding.

The consolidation was approved by the directors of the Company and has received approval from the TSX Venture Exchange.

PLAN is a Canadian based mineral exploration company with its flagship Z1 Zeolite Quarry in British Columbia. PLAN also has a right to earn a 100% interest in the Z2 Zeolite Property near Falkland, BC. Progressive Planet is committed to using mineral resources to provide solutions for a livable planet.

ON BEHALF OF THE BOARD

Signed "Stephen Harpur"
Stephen Harpur, CPA, CGA, CEO

For further information or investor relations inquiries, please contact us:

1-800-910-3072
Investors@progressiveplanet.ca
www.progressiveplanet.ca

Forward-Looking Statements:

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Progressive Planet Solutions Inc.

ReleaseID: 570454

Chemesis International Inc. Announces Share Consolidation

VANCOUVER, BC / ACCESSWIRE / December 16, 2019 / Chemesis International Inc. (CSE:CSI)(OTC:CADMF)(FRA:CWAA) (the "Company" or "Chemesis"), announces that it will complete a consolidation ("Consolidation") of its issued and outstanding common shares on the basis of one (1) post-consolidation common share for each ten (10) pre-Consolidation common shares. Any fraction of a common share will be rounded down to the nearest whole number. As a result of the Consolidation, the outstanding common shares of the Company will be reduced to 11,498,813.

The common shares will begin trading on a consolidated basis and with a new CUSIP number on December 20, 2019.

The Company's name and trading symbol will not change.

Letter of transmittals will be mailed to registered Shareholders and registered Shareholders will be required to deposit their share certificate(s), together with the duly completed letter of transmittal, with Odyssey Trust Company, the Company's registrar and transfer agent. Non-registered Shareholders holding common shares through an intermediary (a securities broker, dealer, bank or financial institution) should be aware that the intermediary may have different procedures for processing the Consolidation than those that will be put in place by the Company for registered Shareholders. If Shareholders hold their common shares through intermediaries and have questions in this regard, they are encouraged to contact their intermediaries.

Outstanding stock options and share purchase warrants will also be adjusted by the Consolidation ratio and the respective exercise prices of outstanding options and share purchase warrants will be adjusted accordingly.

The decision to effect the Consolidation was taken by the Board of Directors of the Company after carefully considering a number of factors, including the significant decline in the Company's share price over the past several months, the significant decline in the market values of many other companies operating in the cannabis sector, and the related challenges companies in the sector are facing in completing financings, particularly equity financings. The Company believes that effecting the Consolidation will be beneficial to the Company in that it is expected to, among other things, provide the Company with greater flexibility in attracting potential financing.

Investor Relations:

ir@chemesis.com
1 (604) 398-3378

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company's business, its product offerings and plans for sales and marketing, including with respect to the Company's expectations regarding its supply and distribution arrangements, ability to realize benefits from its recent contractual arrangements, its plans to continue to develop dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected, including, but not limited to, in relation to executing on and maintaining its supply and distribution arrangements and recent contractual arrangements, in relation to developing dispensaries in Puerto Rico, and its ability to obtain licenses in additional jurisdictions. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

SOURCE: Chemesis International Inc.

ReleaseID: 570449

Bold Ventures Seeks Shareholder Approval for Consolidation Mandate

Not for distribution to U.S. Newswire Services or for dissemination in the United States

TORONTO, ON / ACCESSWIRE / December 16, 2019 / Bold Ventures Inc. (TSXV:BOL) (the "Company" or "Bold") wishes to announce that it has called its Annual General and Special Meeting of Shareholders for Wednesday, January 29, 2019 (the "Annual Meeting") to, among other things, seek shareholder approval to give the Board of Directors discretion to consolidate the Company's common shares on the basis of one (1) post-consolidation common share for up to ten (10) pre-consolidated common shares (the "Consolidation"). If Shareholder approval is obtained, the Consolidation may be effected at a time determined by the Board in the context of the market at the time and announced by a press release of the Company.

Currently there are 125,670,246 common shares issued and outstanding. To illustrate an example, if the Company effects a five (5) to one (1) consolidation, there would be 25,134,049 common shares issued and outstanding after giving effect to the consolidation.

The Company's shares have been trading in the $0.005 to $0.01 range for the last three (3) months and the Company is seeking shareholder approval to the Consolidation to facilitate a private placement at a price of at least $0.05 after giving effect to the consolidation (based upon the minimum pricing rules of the TSX Venture Exchange ("TSXV")). The Board of Directors believes that it is in the best interests of Shareholders for the Board to have the authority to implement the Consolidation. The Consolidation will, among other things, assist the Company in potentially raising additional capital. At this time the high number of shares outstanding and the current market price of the shares makes it difficult to sustain higher share prices. This low share price range results in material limitations on the Company's ability to finance future projects through equity or convertible debt issues. The Consolidation may have the effect of raising, on a proportionate basis, the market price of the common shares. However, implementation of the Consolidation is not likely to have an effect on the actual or intrinsic value of the business of the Company, the common shares or on a Shareholder's proportional ownership in the Company.

There will be no change in the name of the Company. The Consolidation is subject to approval of Shareholders by way of a special resolution approved by 66 2/3% of Shareholders voting at the Annual Meeting. The consolidation is also subject to approval of the TSXV.

The Company and the vendor of the Wilcorp Gold Project have agreed to extend the next optional payment of $6,000 to February 10, 2020.

The Company also reports that Gary Zak has resigned from the Board of Directors. The Company thanks Gary for his years of service.

For additional information about Bold Ventures and our projects please visit www.boldventuresinc.com or contact Bold Ventures Inc. at 416-864-1456.

"David B Graham"
David Graham
President and CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

SOURCE: Bold Ventures Inc.

ReleaseID: 570438

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Energy Transfer LP and Encourages Investors with Losses in Excess of $2,000,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Energy Transfer LP ("Energy Transfer" or "the Company") (NYSE:ET) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 25, 2017 and November 11, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 20, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Energy Transfer engaged in bribery and other improper conduct to secure permits for the Mariner East pipeline project. This activity put the Company and its employees at risk of government and regulatory action. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Energy Transfer, investors suffered damages.

Join the case to recover your losses. Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570434

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Net 1 UEPS Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Net 1 UEPS Technologies, Inc. ("UEPS" or "the Company") (NASDAQ:UEPS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 12, 2018 and November 8, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before February 3, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. UEPS failed to maintain effective controls on financial reporting. The Company misclassified its investment in Cell C Proprietary Limited. The Company's financial statements for fiscal year 2018 overstated its income. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about UEPS, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570432